APVO News and Press, Aptevo Therapeutics Inc. From 07/21/20

SEATTLE, WA / ACCESSWIRE / July 21, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, has engaged Piper Sandler to sell its RUXIENCE ® ...

Aptevo Therapeutics ( APVO +4.6% ) collects in full $0.75M placed into an escrow account for working capital adjustments. More news on: Aptevo Therapeutics Inc., Healthcare stocks news, Read more ...

SEATTLE, WA / ACCESSWIRE / June 29, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, announced today that it has collected in full the $750,...

Aptevo Therapeutics ( APVO +40.7% ) to receive a seven year quarterly royalty from Pfizer related to sales of RUXIENCE (rituximab biosimilar), which was approved by the FDA in July 2019 and launched by Pfizer in the US and Japan in early 2020. More news on: Apt...

Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSolutions SEATTLE, WA / ACCESSWIRE / June 25, 2020 / Aptevo Therapeutics Inc. (NA...

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High Doses Which Were Observed in a Urelumab Analogue in a Side-by-Side Comparison ALG.APV-527 is a Novel Immunotherapeutic Bispecific Candidate...

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Ongoing Reports Preliminary Evidence of a Potential Clinical Response Observed with APVO436 Sharpens Focus on Novel ADAPTI...

SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The N...

Aptevo Therapeutics (NASDAQ: APVO ): FY GAAP EPS of -$1.09 beats by $0.04 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Reports Preliminary Evidence of Clinical Activity of APVO436; Dosing in Cohort 6 to Begin Shortly Achieves Record Annual IXINITY ® Net Reve...